A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants

Chronic Graft vs Host Disease Clinical Trial

Official title:
A Retrospective/Prospective, Multicenter, Non-interventional, Historical Control Study Investigating Comparative Effectiveness of IMBRUVICA in Steroid Dependent/Refractory cGVHD Patients

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of ibrutinib compared to conventional salvage treatments in participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (modified National Institutes of Health [NIH] response defined complete response [CR] and partial response [PR]) at Week 24.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04852692
Study type	Observational
Source	Janssen Korea, Ltd., Korea
Contact
Status	Terminated
Phase
Start date	June 21, 2021
Completion date	August 6, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03683498` - Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease	Phase 1
Completed	`NCT01221766` - Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease	N/A
Active, not recruiting	`NCT02067832` - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Active, not recruiting	`NCT02759731` - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1/Phase 2
Recruiting	`NCT05095649` - Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib	Phase 2
Recruiting	`NCT02669251` - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1/Phase 2